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Abstract
Background: Psychiatric disorders are highly prevalent and associated with great symptomatic, functional, and
health economic burdens. Psychotherapy is among the recommended and used interventions for most psychiatric
disorders and is becoming widely accessible in mental health systems. The effects of specific forms of psychotherapy
(e.g., psychodynamic therapies, cognitive and behavioral therapies, humanistic therapies, and systemic therapies) have
been assessed previously in systematic reviews, but the appropriate psychotherapy duration for psychiatric disorders
has not been reviewed. The aim of this systematic review will be to synthesize the evidence of the effects of short-
term compared with long-term psychotherapy for all adult psychiatric disorders.
Methods/design: A comprehensive search for relevant published literature will be undertaken in Cochrane Central
Register of Controlled Trials (CENTRAL), Medical Literature Analysis and Retrieval System Online (MEDLINE), Excerpta
Medica database (EMBASE), Latin American and Caribbean Health Sciences Literature (LILACS), PsycINFO, Science
Citation Index Expanded (SCI-EXPANDED), Social Sciences Citation Index (SSCI), Conference Proceedings Citation
Index—Science (CPCI-S), and Conference Proceedings Citation Index—Social Science & Humanities (CPCI-SSH) to
identify relevant trials. We will search all databases from their inception to the present. We will include randomized
clinical trials comparing a short-term and a long-term version of the same psychotherapy type for adult psychiatric
disorders including attention deficit hyperactivity disorder, psychotic disorders, depressive disorders, bipolar disorders,
anxiety disorders, obsessive-compulsive disorder, trauma- and stressor-related disorders, eating disorders, and
personality disorders (as defined by standardized diagnostic criteria). We will rely on the trialists defining their
compared interventions as short term and long term (or similar terminology). Primary outcomes will be
quality of life, serious adverse events, and symptom severity. Secondary outcomes will be suicide or suicide
attempts, self-harm, and level of functioning. Two review authors will independently extract data and perform
risk of bias assessment using the Cochrane risk of bias tool. A meta-analysis will be performed as recommended by the
Cochrane Handbook for Systematic Review of Interventions, bias will be assessed with domains, and Trial Sequential
Analysis will be conducted to control random errors. Certainty of the evidence will be assessed by GRADE.
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Discussion: As psychotherapy is among the treatments of choice for most adult psychiatric disorders, a systematic
review evaluating the benefits and harms of short-term compared with long-term psychotherapy is urgently needed. It
is the hope that this review will be able to inform best practice in treatment and clinical research of these highly
prevalent and burdensome disorders.
Systematic review registration: PROSPERO CRD42019128535
Keywords: Psychotherapy duration, Psychiatric disorders, Short-term psychotherapy, Long-term psychotherapy, Dose-
effect
Background
It is estimated that each year, 38.2% of the European
population suffer from a psychiatric disorder [1]. The
economic burden from psychiatric disorders is excessive,
not only because of high direct health care costs, but
also because of indirect costs like sick days, disability,
and early retirement [1]. Psychotherapy is among the
recommended and widely used interventions for most
disorders [2]. Specific types of psychotherapy have
already been systematically reviewed, but the appropriate
length of psychotherapy for all adult psychiatric disor-
ders has not been reviewed previously. To present a
complete overview of the evidence and to increase the
statistical power, we will therefore in the present review
include any adult psychiatric disorder. The major cat-
egories of adult psychiatric disorders listed in the Diag-
nostic and Statistical Manual of Mental Disorders, 5th
edition (DSM-V) [3] are the following.
Attention Deficit Hyperactivity Disorder (ADHD) is
characterized by a persistent pattern of inattention and/
or hyperactivity and impulsivity that significantly inter-
feres with functioning and development [3]. ADHD is
one of the most common psychiatric disorders of child-
hood and adolescence, and it often persists into adult-
hood. The predominant characteristics of adult ADHD
differ from typical ADHD characteristics in children.
Symptoms of hyperactivity or impulsivity are typically
less obvious in adults, whereas symptoms of inattention
are more dominant [4]. Epidemiologic studies of adult
ADHD have estimated the current prevalence to be 4.4%
in the USA and 3.4% internationally [4, 5]. The total
economic burden of ADHD in America has been esti-
mated to be 31.6 billion US dollars in 2010 [6] including
both direct costs, other health care costs, health care
costs for family members, and work loss of patients and
their relatives.
Psychotic disorders are characterized by abnormalities
in one or more of the following five domains: delusions,
hallucinations, disorganized thinking, disorganized or
abnormal motor behavior, and negative symptoms [3].
The estimated annual prevalence of all psychotic
disorders is 2.6% [7]. The most common psychotic
disorder is schizophrenia with an estimated median
lifetime prevalence of 4.0 per 1000 and a lifetime
morbid risk of 7.2 per 1000 [8]. Annual costs for the
schizophrenia population have been systematically
reviewed and estimated to range from 94 million to 102
billion US dollars. Indirect costs contributed to 50–85% of
the total costs associated with schizophrenia [9].
Bipolar disorders are characterized by serious mood
changes involving mood elevation (mania or hypo-
mania) either alone or followed by major depressive
episodes [3]. Bipolar disorder subtypes include bipolar
I and bipolar II. Bipolar I disorder is associated with
manic episodes nearly always followed by major de-
pressive and hypomanic episodes. Bipolar II disorder
is associated with at least one hypomanic episode, at
least one major depressive episode, and the absence
of manic episodes. The international annual preva-
lence is estimated to be 0.4% for bipolar I disorder
and 0.3% for bipolar II disorder [10]. In 2009, the
estimated annual direct and indirect costs of bipolar I
and II disorders were 30.7 and 120.3 billion US dol-
lars, respectively [11].
Depressive disorders are characterized by the pres-
ence of a sad, empty, and irritable mood often ac-
companied by somatic and cognitive changes resulting
in significant functional impairment [3]. The most
common depressive disorder is major depressive dis-
order (unipolar depression) with an annual prevalence
of approximately 7% both in Europe [1] and in the
USA [12]. The estimated annual economic burden of
adults with major depressive disorder, including direct
medical costs, workplace costs, and costs associated
with comorbidities exceeded 200 billion US dollars
[13] in the USA in 2010.
Anxiety disorders are characterized by excessive and
counterproductive feelings of fear and anxiety often ac-
companied by behavioral disturbances such as pervasive
avoidance behaviors [3]. Different anxiety disorders exist,
which differ from one another in the types of objects or
situations that induce hyperarousal or avoidance behav-
ior [3]. The prevalence of anxiety disorders is estimated
to be 18% in the USA [14] and 14% in European coun-
tries [1], placing them among the most prevalent
psychiatric disorders worldwide. Costs associated with
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anxiety disorders have previously been reported to be
46.6 billion US dollars in the USA [15] including both
direct and indirect costs.
Obsessive-compulsive disorder (OCD) is characterized
by recurrent intrusive thoughts, images, or urges (obses-
sions) with or without repetitive mental or behavioral
acts (compulsions) [3]. OCD among adults has an an-
nual prevalence of 1.2% and a lifetime prevalence of
2.3% [16, 17]. The annual economic burden of OCD is
estimated to be 2272 euros per patient when including
both direct and indirect costs [18].
Trauma- and stressor-related disorders are character-
ized by psychological distress following exposure to a
traumatic or stressful event. The most common trauma
disorder is post-traumatic stress disorder (PTSD) [3].
PTSD is a prevalent and disabling disorder associated
with delayed help seeking [19]. The estimated annual
prevalence of PTSD is 2% in Europe [1] and 4.7% in the
USA [20], and the estimated lifetime prevalence is 3.9%
across 26 countries ranging from low to high income
[21]. The total costs of PTSD per patient have been esti-
mated to 1082 million euros including both direct and
indirect costs [18].
Eating disorders are characterized by a persistent
disturbance in eating behavior resulting in altered con-
sumption or absorption of food that significantly impairs
health and psychosocial functioning [3]. The most
common eating disorders are anorexia nervosa, bulimia
nervosa, and binge-eating disorder. Lifetime prevalence
of anorexia nervosa, bulimia nervosa, and binge-eating
disorder are estimated to be 0.9, 1.5, and 3.5%, respect-
ively, among women and 0.3, 0.5, and 2.0%, respectively,
among men [22]. The estimated annual prevalence of
eating disorders is 0.9% in the European population [1].
Annual costs per patient are estimated to range from
1288 to 8042 US dollars [23].
Personality disorders are characterized by enduring
and inflexible patterns of emotional, behavioral, and
interpersonal problems that deviate markedly from cul-
tural expectations. According to DSM-V, the following
nine personality disorders exist. Personality disorders
onset in adolescence or early adulthood and are associ-
ated with great psychosocial distress and impairment [3].
In a systematic review of the economic burden of
personality disorders, the estimated direct and indirect
costs were 11,126 euros for patients 12 months prior to
seeking treatment. Direct medical costs accounted for
two thirds of these costs, while the remaining costs were
related to productivity losses [24].
Description of the interventions
Different schools of psychotherapy exist. They are often
divided into the following categories: psychodynamic
therapies, cognitive and behavioral therapies, humanistic
therapies, and systemic therapies [2].
Psychodynamic (or psychoanalytical) therapies encom-
pass the many approaches that are influenced by Freud’s
psychoanalysis but have developed into different
independent schools [2]. Traditionally, psychodynamic
therapies have been considered as long-term therapies,
perhaps due to the notion that the uncovering of uncon-
scious emotions and conflicts cannot be achieved with a
fixed time limit [25]. Long-term psychoanalytical psy-
chotherapy has previously been systematically reviewed
yielding different results [26, 27]. Today, different
lengths of psychodynamic therapies have been developed
to treat different forms of psychopathology. In addition
to traditional psychoanalysis, examples of long-term
psychodynamic treatments are transference-focused
psychotherapy (TFP), a psychodynamic treatment rooted
in object relations theory lasting up to 3 years [28, 29],
and mentalization-based therapy [30], an 18-month psy-
chodynamic treatment rooted in attachment theory.
Both are developed specifically to treat borderline
personality disorder. Further, different variations of
short-term psychodynamic therapy have been developed
to treat a variation of common psychiatric disorders,
most notably anxiety disorders, depressive disorders,
certain behavior disorders, and personality disorders
[31]. Short-term psychodynamic therapies vary in treat-
ment duration but typically last between 12 and 24
sessions [31].
Cognitive and behavioral therapies (CBT) encompass
many integrative approaches. Historically, behavior ther-
apy (first wave CBT) developed from the learning theor-
ies of Pavlov [32] and Skinner [33]. An integration of a
cognitive component to classical behavioral theories was
first established by Beck [34, 35], who developed what is
now often referred to as second-wave CBT. CBT is now
often delivered as a short-term treatment, typically last-
ing between 12 and 20 sessions, for a variation of com-
mon psychiatric disorders like depressive disorders [34],
anxiety disorders [36], obsessive-compulsive disorder
[37], personality disorders [38], and eating disorders
[39]. Different durations of CBT are also available for the
treatment of schizophrenia [40, 41]. Today, so-called
third-wave cognitive therapies have emerged, character-
ized by more integrative approaches to psychotherapy,
incorporating techniques from Buddhist mindfulness,
psychodynamic therapies, or Gestalt therapy [2]. These
include dialectical behavior therapy [42] and schema-
focused therapy (SFT) [29, 43], which are both long-
term therapies for borderline personality disorder (up to
3 years), and acceptance and commitment therapy
(ACT) [44] and compassion-focused therapy (CFT) [45],
which are often delivered as short-term treatments for
various psychiatric disorders [46, 47].
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Humanistic therapies are characterized by psychother-
apy approaches derived from humanistic and existential-
ist philosophy. Major approaches within this orientation
are person-centered therapy [48], Gestalt therapy [49],
existential psychotherapy [50], and process-experiential/
emotion-focused therapy [51]. All humanistic therapies
share the notion of empathic understanding, the promo-
tion of in-therapy experiencing, and a belief in the
uniquely human growth tendency by applying a consist-
ent person-centered view involving concern for each pa-
tient’s individual experience and differing needs [2].
Humanistic therapies have not been developed to treat
specific types of disorders and are traditionally consid-
ered open-ended, which is also aligned with the person-
centered way of thinking. However, different lengths of
humanistic therapies have been studied, e.g., PE-EFT as
a short-term treatment (down to 5 weeks) for depressive
disorders [52] and as a 20-week treatment for trauma-
related disorders [53].
Systemic therapies are characterized by a systemic ap-
proach to psychotherapy defining patients’ problems as
contextually rather than individually derived. Most often,
the context of interest is the partner or the family, but it
can also be a broader context, such as the extended fam-
ily or a classroom [2]. Different systemic therapies exist
for different types of psychopathology. Examples are
family-based therapy for eating disorders [54], attachment-
based family therapy for depressed adolescents (ABFT)
[55], parent management training for childhood conduct
disorders [56], psychoeducational family interventions for
schizophrenia [57] and bipolar disorder [58], and systemic
treatments for substance-use disorders [59, 60]. Different
lengths of systemic therapies exist. However, the typical
duration is between 10 and 25 sessions.
Other forms of psychotherapy exist, e.g., interpersonal
therapy (IPT) [61] or cognitive-analytic therapy (CAT)
[62]. However, it is beyond the scope of this review to
mention all new approaches to psychotherapy since the
field is constantly expanding. Further, despite the exist-
ence of well-established manualized and evidence-based
approaches to psychotherapy, a large proportion of prac-
ticing psychotherapists define themselves as eclective or
integrative [63].
How the interventions might work
It is a common opinion among clinicians and re-
searchers that patients suffering from complex psychi-
atric distress require longer and more intensive
psychotherapy [27]. Complex psychiatric distress can be
defined as disorders, which by definition are enduring
and inflexible [27], such as personality disorders or
schizophrenia, chronic psychiatric disorders (defined as
lasting at least a year), or multiple psychiatric disorders.
A related assumption is that complex and severe
problems typically take longer to improve than less com-
plex or acute psychiatric distress [25, 64]. This is due to
the inherent inflexibility of the psychopathology and the
complexity of the required therapeutic techniques. Such
potential therapeutic techniques could be provocation of
affect or working with the therapeutic alliance [25].
These are techniques that are potentially hard to carry
out when faced with time constraints. However, it is
often argued that such techniques are essential to effect-
ive psychotherapy [65].
In contrast, one could argue that long-term therapies
can become counterproductive, given that the same
therapeutic techniques will be repeated for a long period
of time without continuous assessment of their effects.
It is possible that given the limited therapeutic time,
planned short-term psychotherapy forces both patients
and therapists to establish and maintain a focus
throughout the treatment process [66]. Further, issues
regarding termination of treatment are particularly im-
portant when conducting short-term psychotherapy,
where concerns about termination are, almost by defin-
ition, always present [67, 68]. Thus, a possible advantage
of short-term therapies is that both therapist and patient
are forced to address difficult themes associated with
separation and loss from the very beginning instead of
postponing them for later.
Why is it important to do this review?
It is essential to investigate the optimal duration of
psychotherapy for psychiatric disorders, because of the
potential patient and health economic burden from long-
term psychotherapy and because of the potential harmful
effects of terminating treatment prematurely [69]. If short-
term psychotherapy is the optimal treatment approach,
then this could result in a reduction of waitlists and thus a
greater access to evidence-based care. On the contrary, if
long-term psychotherapy is the most optimal treatment,
then it becomes sensible for mental health systems to in-
vest in these treatments, as they would translate into
greater health and occupational benefits [70].
The relationship between the number of sessions (dose)
and patient improvement (effect) in psychotherapy has
previously been studied with mixed results [70, 71]. There
are studies indicating that increased number of sessions is
associated with diminishing results [72]. There are also
studies indicating that the speed of improvement is
dependent on patients pretreatment functioning [73] and
that some patients require different dosages to receive the
same effect. However, most research on the association
between dose and effect is based on uncontrolled studies
[70–72, 74, 75] which can only show that patients improve
during treatment. Whether this improvement can be at-
tributed to the treatment, can only be established with
randomized controlled trials, in which shorter and longer
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therapies are directly compared. A systematic review of
such randomized clinical trials might allow us to assess
the safety profile of the different treatment options
directly. We are already aware of two randomized clinical
trials comparing a short-term and a long-term version of
the same psychotherapy type for one or more adult psy-
chiatric disorders [76, 77]. We have performed a prelimin-
ary literature search in the Cochrane Database of
Systematic Reviews (search terms, short-term or brief and
long-term or standard psychotherapy) for previous sys-
tematic reviews comparing a short-term and a long-term
version of the same psychotherapy type for one or more
adult psychiatric disorders. We identified 1114 hits. From
this preliminary literature search, we have only identified
one empty systematic review [78].
The present systematic review aims at forming the
basis for evidence-based guideline recommendations for
the optimal duration of psychotherapy for adult psychi-
atric disorders taking bias risk (systematic errors), play
of chance (random errors), and certainty of the findings
into consideration. The objective of this review will be
to assess the beneficial and harmful effects of short-term
psychotherapy compared with long-term psychotherapy
for adult psychiatric disorders.
Methods
The present protocol has been registered in the PROS-
PERO database (registration number, CRD42019128535)
and is being reported in accordance with the report-
ing guidance provided in the Preferred Reporting
Items for Systematic Reviews and Meta-Analysis
Protocols (PRISMA-P) statement [79, 80] (see check-
list in Additional file 1).
Criteria for considering studies for this review
Types of studies
We will include randomized clinical trials irrespective of
trial design, setting, publication status, publication year,
and language. We will not include quasi-randomized tri-
als and observational studies.
Types of participants
Adults (as defined by trialists) with a primary diagnosis
of any of the following psychiatric disorders: attention
deficit hyperactivity disorder, psychotic disorders, de-
pressive disorders, bipolar disorders, anxiety disorders,
obsessive-compulsive disorder, trauma- and stressor-
related disorders, eating disorders, and personality disor-
ders, as defined by standardized diagnostic criteria from
either ICD-10 [81], DSM-5 [3], or earlier versions (ICD-
10 codes: F20–29, F30–39, F40–49, F50–59, F60–69,
and F90–90.9). Participants will be included irrespective
of sex and comorbidities.
Types of interventions
Experimental group: we will accept any type of short-
term psychotherapy (or similar terms used by the
trialists).
Control group: we will accept any type of long-term
psychotherapy (or similar terms used by the trialists).
We will rely on the trialists defining their compared in-
terventions as short-term and long-term (or similar ter-
minology). We will include trials comparing a short-term
and a long-term version of the same psychotherapy type
(e.g., short-term psychodynamic therapy compared to
long-term psychodynamic therapy). We will not include
trials comparing short-term psychotherapy (e.g., short-
term cognitive behavioral therapy) with a different type of
psychotherapy (e.g., long-term psychodynamic therapy)
delivered as long-term therapy. Further, we will include
trials with the same dose (sessions) but with different fre-
quencies, e.g., 12 sessions delivered over 6 weeks com-
pared to 12 sessions delivered over 12 weeks.
Outcome measures
Primary outcomes
1. Quality of life (continuous data)
2. Serious adverse events (dichotomous data). We will
use the International Conference on Harmonisation
of technical requirements for registration of
pharmaceuticals for human use—Good Clinical
Practice (ICH-GCP) definition of a serious adverse
event, which is any untoward medical occurrence
that resulted in death, was life-threatening, required
hospitalization or prolonging of existing
hospitalization and resulted in persistent or
significant disability or jeopardized the patient [82].
If the trialists do not use the ICH-GCP definition,
we will include the data if the trialists use the term
“serious adverse event.” If the trialists do not use
the ICH-GCP definition nor use the term serious
adverse event, then we will also include the data, if
the event clearly fulfills the ICH-GCP definition for
a serious adverse event.
3. Symptom severity assessed by any valid disease-
specific symptom scale (continuous data). Symptoms
will be analyzed separately for each disorder.
Secondary outcomes
1. Suicide or suicide attempts as defined by trialists
(dichotomous data)
2. Self-harm as defined by trialists (dichotomous data)
3. Level of functioning as defined by trialists
(continuous data)
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Assessment time points
The primary assessment time point will be the time
point closest to the end of treatment in the trials’ long-
term intervention group for all outcomes. For example,
if a trial compares a 6-month and a 12-month version of
the same psychotherapy type and outcomes are assessed
every second month throughout the trial, we will select
the assessment time point closest to the end of the
12-month intervention as the primary assessment
time point for all outcomes. We will secondarily as-
sess all outcomes at maximum follow-up if longer
term follow-up is assessed.
Search methods for identification of studies
Electronic searches
We will search Cochrane Central Register of Controlled
Trials (CENTRAL), Medical Literature Analysis and
Retrieval System Online (MEDLINE), Excerpta Medica
database (EMBASE), Latin American and Caribbean
Health Sciences Literature (LILACS), PsycINFO, Science
Citation Index Expanded (SCI-EXPANDED), Social
Sciences Citation Index (SSCI), Conference Proceedings
Citation Index—Science (CPCI-S), and Conference
Proceedings Citation Index—Social Science & Human-
ities (CPCI-SSH) to identify relevant trials. We will
search all databases from their inception to the present.
For a detailed search strategy for all electronic databases,
see Additional file 2. The search strategy for PsycINFO
will be given at the review stage.
Searching other resources
The reference lists of relevant publications will be
checked for any unidentified randomized trials. We will
contact the authors of included studies by email asking
for unpublished randomized trials. Further, we will
search for ongoing trials on the following:
 ClinicalTrials.gov (www.clinicaltrials.gov)
 Google Scholar (https://scholar.google.dk/)
 The Turning Research into Practice (TRIP) Database
(https://www.tripdatabase.com/)
 European Medicines Agency (EMA) (http://www.ema.
europa.eu/ema/)
 US Food and Drug Administration (FDA)
(www.fda.gov)
 China Food and Drug Administration (CFDA)
(http://eng.sfda.gov.cn/WS03/CL0755/)
 Medicines and Healthcare Products Regulatory Agency
(https://www.gov.uk/government/organisations/
medicines-and-healthcare-products-regulatoryagency)
 The World Health Organization (WHO) International
Clinical Trials Registry Platform (ICTRP) search portal
(http://apps.who.int/trialsearch/)
 Cochrane Database of Systematic Reviews
 http://www.evidencebasedpsychotherapies.org/index.
php?id=25
Additionally, we will hand search conference abstracts
from psychiatry conferences for relevant trials. We will
also consider relevant-for-the-review unpublished and
gray literature trials if we identify these.
Data collection and analysis
We will perform the review following recommendations
of the Cochrane Collaboration [83]. The analyses will be
performed using Trial Sequential Analysis [84] and Stata
version 16 (StataCorp LLC, College Station, TX, USA)
[85].
Selection of studies
Two authors (SJ and SS) will independently screen titles
and abstracts. We will retrieve all relevant full-text study
reports/publications, and two review authors (SJ and SS)
will independently screen the full text and identify and
record reasons for exclusion of the ineligible studies. We
will resolve any disagreement through discussion, or if
required, we will consult a third person (JCJ). Trial
selection will be displayed in an adapted flow diagram as
per the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) statement [86].
Data extraction and management
Two authors (SJ and SS) will independently extract data
from included trials. Disagreements will be resolved by
discussion with a third author (JCJ). We will assess
duplicate publications and companion papers of a trial
together to evaluate all available data simultaneously
(maximize data extraction, correct bias assessment). We
will contact the trial authors by email to specify any add-
itional data, which may not have been reported suffi-
ciently or at all in the publication.
Trial characteristics
We will extract the following data: bias risk components
(as defined below), trial design (parallel, factorial, or
crossover), number of intervention arms, length of
follow-up, estimation of sample size, and inclusion and
exclusion criteria.
Participant characteristics and diagnosis
We will extract the following data: number of random-
ized participants, number of analyzed participants, num-
ber of participants lost to follow-up/withdrawals/
crossover, compliance with interventions, age range
(mean or median), sex ratio, and type of psychiatric
disorder.
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We will additionally report the proportion of partici-
pants in the compared groups who receive psychotropic
medication.
Short-term psychotherapy characteristics
We will extract the following data: short-term psycho-
therapy type, treatment duration, number of sessions
(dose), session lengths (minutes), number of sessions per
week, and treatment format.
Long-term psychotherapy characteristics
We will extract the following data: long-term psycho-
therapy type, treatment duration, number of sessions
(dose), session lengths (minutes), number of sessions per
week, and treatment format.
Co-intervention characteristics
We will extract the following data: type of co-intervention,
treatment duration of co-intervention, number of sessions
(or dose), and treatment format.
Outcomes
All outcomes listed above will be extracted from each
randomized clinical trial, and we will identify if out-
comes are incomplete or selectively reported according
to the criteria described later in “incomplete outcome
data” bias domain and “selective outcome reporting” bias
domain.
Notes
Funding of the trial and notable conflicts of interest
of trial authors will be extracted, if available. We will
note in the “Characteristics of included studies” table
if outcome data were not reported in a usable way.
Two review authors (SJ and SS) will independently
transfer data into the Stata file [85]. Disagreements
will be resolved through discussion, or if required, we
will consult with a third author (JCJ).
Assessment of risk of bias in included studies
We will use the instructions given in the Cochrane
Handbook for Systematic Reviews of Interventions [83]
in our evaluation of the methodology and hence the
risk of bias of the included trials. We will evaluate
the methodology in respect of the following:
 Random sequence generation
 Allocation concealment
 Blinding of participants and treatment providers
 Blinding of outcome assessment
 Incomplete outcome data
 Selective outcome reporting
 Other risk of bias
 Overall risk of bias
Random sequence generation
 Low risk: If sequence generation was achieved using
computer random number generator or a random
number table. Drawing lots, tossing a coin, shuffling
cards, and throwing dice will also be considered
adequate if performed by an independent
adjudicator.
 Unclear risk: If the method of randomization was
not specified, but the trial was still presented as
being randomized
 High risk: If the allocation sequence was not
randomized or only quasi-randomized. These trials
will be excluded.
Allocation concealment
 Low risk: If the allocation of patients was performed
by a central independent unit, on-site locked com-
puter, identical-looking numbered sealed envelopes,
or containers prepared by an independent
investigator
 Uncertain risk: If the trial was classified as
randomized but the allocation concealment process
was not described
 High risk: If the allocation sequence was familiar to
the investigators who assigned participants
Blinding of participants and treatment providers
 Low risk: If the participants and the treatment
providers were blinded to intervention allocation
and this was described
 Uncertain risk: If the procedure of blinding was
insufficiently described
 High risk: If blinding of participants and the
treatment providers was not performed
Blinding of outcome assessment
 Low risk of bias: If it was mentioned that outcome
assessors were blinded and this was sufficiently
described
 Uncertain risk of bias: If it was not mentioned if the
outcome assessors in the trial were blinded or the
extent of blinding was insufficiently described
 High risk of bias: If no blinding or incomplete
blinding of outcome assessors was performed
Incomplete outcome data
 Low risk of bias: If missing data were unlikely to
make treatment effects depart from plausible values.
This could be either (1) there were no drop-outs or
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withdrawals for all outcomes or (2) the numbers and
reasons for the withdrawals and drop-outs for all
outcomes were clearly stated and could be described
as being similar to both groups. Generally, the trial
is judged as at a low risk of bias due to incomplete
outcome data if drop-outs are less than 5%.
However, the 5% cut-off is not definitive.
 Uncertain risk of bias: If there was insufficient
information to assess whether missing data were
likely to induce bias on the results.
 High risk of bias: If the results were likely to be
biased due to missing data either because the
pattern of drop-outs could be described as being dif-
ferent in the two intervention groups or the trial
used improper methods in dealing with the missing
data (e.g., last observation carried forward).
Selective outcome reporting
 Low risk of bias: If a protocol was published before
or at the time the trial begun and the outcomes
specified in the protocol were reported on
 Uncertain risk of bias: If no protocol was published
 High risk of bias: If the outcomes in the protocol
were not reported on
Other risk of bias
 Low risk of bias: If the trial appears to be free of
other components (for example, academic bias or
for-profit bias) that could put it at risk of bias
 Unclear risk of bias: If the trial may or may not be
free of other components that could put it at risk of
bias
 High risk of bias: If there are other factors in the
trial that could put it at risk of bias (for example,
authors conducted trials on the same topic, for-
profit bias)
Overall risk of bias
 Low risk of bias: The trial will be classified as overall
“low risk of bias” only if all of the bias domains
described in the above paragraphs are classified as
low risk of bias.
 High risk of bias: The trial will be classified as “high
risk of bias” if any of the bias risk domains described
above are classified as “unclear” or high risk of bias.
We will assess the domains “blinding of outcome as-
sessment,” “incomplete outcome data,” and “selective
outcome reporting” for each outcome result. Thus, we
can assess the bias risk for each outcome assessed in
addition to each trial. Our primary conclusions will be
based on the results of our primary outcome results with
overall low risk of bias. Both our primary and secondary
conclusions will be presented in the summary of findings
tables.
Differences between protocol and the review
We will conduct the review according to this published
protocol and report any deviations from it in the “Differ-
ences between the protocol and the review” section of
the systematic review.
Measures of treatment effect
Dichotomous outcomes We will calculate risk ratios
(RRs) with 95% confidence interval (CI) for dichotomous
outcomes, as well as the Trial Sequential Analysis-
adjusted CIs (see below).
Continuous outcomes We will calculate the mean dif-
ferences (MDs) and consider calculating the standard-
ized mean difference (SMD) with 95% CI for continuous
outcomes. We will also calculate trial sequential
analysis-adjusted CIs (see below).
Dealing with missing data
We will, as the first option, contact all trial authors to
obtain any relevant missing data (i.e., for data extraction
and for assessment of risk of bias, as specified above).
Dichotomous outcomes We will not impute missing
values for any outcomes in our primary analysis. In our
sensitivity analyses (see paragraph below), we will im-
pute data.
Continuous outcomes We will primarily analyze scores
assessed at single time points. If only changes from base-
line scores are reported, we will analyze the results to-
gether with follow-up scores [83]. If standard deviations
(SDs) are not reported, we will calculate the SDs using
trial data, if possible. We will not use intention-to-treat
data if the original report did not contain such data. We
will not impute missing values for any outcomes in our
primary analysis. In our sensitivity analysis (see para-
graph below) for continuous outcomes, we will impute
data.
Assessment of heterogeneity
We will primarily investigate forest plots to visually as-
sess any sign of heterogeneity. We will secondly assess
the presence of statistical heterogeneity by chi2 test
(threshold P < 0.10) and measure the quantities of het-
erogeneity by the I2 statistic [87, 88]. We will investigate
possible heterogeneity through subgroup analyses. We
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may ultimately decide that a meta-analysis should be
avoided [83].
Assessment or reporting biases
We will use a funnel plot to assess reporting bias if ten
or more trials are included. We will visually inspect fun-
nel plots to assess the risk of bias. We are aware of the
limitations of a funnel plot (i.e., a funnel plot assesses
bias due to small sample size). From this information,
we assess possible reporting bias. For dichotomous out-
comes, we will test asymmetry with the Harbord test
[89] if τ2 is less than 0.1 and with the Rücker test if τ2 is
more than 0.1. For continuous outcomes, we will use the
regression asymmetry test [90] and the adjusted rank
correlation [91].
Unit of analysis issues We will only include random-
ized clinical trials. For trials using crossover design, only
data from the first period will be included [83, 92].
There will therefore not be any unit of analysis issues.
We will not include cluster randomized trials.
Data synthesis
Meta-analysis We will undertake the meta-analysis ac-
cording to the recommendations stated in the Cochrane
Handbook for Systematic Reviews of Interventions [83],
Keus et al. [93], and the eight-step assessment suggested
by Jakobsen et al. [94]. We will use the statistical soft-
ware Stata version 16 [85] to analyze data. We will assess
our intervention effects with both random-effects meta-
analyses [95] and fixed-effects meta-analyses [96]. We
will use the more conservative point estimate of the two
[94]. The more conservative point estimate is the esti-
mate closest to zero effect. If the two estimates are simi-
lar, we will use the estimate with the widest CI. We
assess a total of six primary and secondary outcomes,
and we will therefore consider a P value of 0.014 or less
as the threshold for statistical significance [94]. We will
investigate possible heterogeneity through subgroup ana-
lyses. Ultimately, we may decide that a meta-analysis
should be avoided [83]. We will use the eight-step pro-
cedure to assess if the thresholds for significance are
crossed [94]. Our primary conclusion will be based on
results with low risk of bias [94]. Where multiple trial
arms are reported in a single trial, we will include only
the relevant arms. If two comparisons are combined in
the same meta-analysis, we will halve the control group to
avoid double-counting [83]. Trials with a factorial design
will be included. In case of, e.g., a 2 × 2 factorial designed
trial, the two groups receiving short-term interventions
will be considered short-term control groups, while the
two groups receiving long-term control interventions will
be considered long-term control groups. If quantitative
synthesis is not appropriate due to considerable hetero-
geneity or a small number of included trials, we will report
the results in a narrative way.
Trial sequential analysis Traditional meta-analysis runs
the risk of random errors due to sparse data and repetitive
testing of accumulating data when updating reviews. We
wish to control the risks of type I errors and type II errors.
We will therefore perform Trial Sequential Analysis on
the outcomes, in order to calculate the required informa-
tion size (that is, the number of participants needed in a
meta-analysis to detect or reject a certain intervention ef-
fect) and the cumulative Z-curve’s breach of relevant
trial sequential monitoring boundaries [84, 97–104].
A more detailed description of trial sequential analysis
can be found in the trial sequential analysis manual
[103] and at http://www.ctu.dk/tsa/.
For dichotomous outcomes, we will estimate the re-
quired information size based on the observed propor-
tion of patients with an outcome in the control group
(the cumulative proportion of patients with an event in
the control groups relative to all patients in the control
groups), a relative risk reduction of 20%, an alpha of
1.4% for all our outcomes, a beta of 20%, and the ob-
served diversity as suggested by the trials in the meta-
analysis. For continuous outcomes, we will in the trial
sequential analysis use the observed SD, a mean differ-
ence of the observed SD/2, an alpha of 1.4% for all out-
comes, a beta of 20%, and the observed diversity as
suggested by the trials in the meta-analysis.
Subgroup analysis and integration of heterogeneity
Subgroup analysis We will perform the following sub-
group analyses when analyzing the primary outcomes
(quality of life, serious adverse events, and symptom
severity).
1. High risk of bias trials compared to low risk of bias
trials
2. Types of psychiatric disorders
3. Types of psychotherapy comparisons
4. Trials above and below the mean difference in
intervention lengths
We will use the formal test for subgroup interactions
in Stata [85].
Sensitivity analysis To assess the potential impact of
the missing data for dichotomous outcomes, we will per-
form the two following sensitivity analyses on both the
primary and secondary outcomes.
Juul et al. Systematic Reviews           (2019) 8:169 Page 9 of 13
 “Best-worst-case” scenario: We will assume that all
participants lost to follow-up in the short-term
experimental group had no serious adverse event,
had no suicides, had no suicide attempts, and had
no self-harm and that all those participants lost to
follow-up in the long-term control group did not
survive, had a serious adverse event, had a suicide
attempt, and had at least one episode of self-harm.
 “Worst-best-case” scenario: We will assume that all
participants lost to follow-up in the short-term con-
trol group did not survive, had serious adverse
event, had a suicide attempt, and had at least one
episode of self-harm and that all those participants
lost to follow-up in the long-term control group
have survived, had no serious adverse event, had no
suicide attempts, and had no self-harm.
We will present results of both scenarios in our re-
view. When analyzing quality of life, symptom severity,
and level of functioning, a “beneficial outcome” will be
the group mean plus two standard deviations (SDs) (we
will secondly use one SD in another sensitivity analysis)
of the group mean and a “harmful outcome” will be the
group mean minus two SDs (we will secondly use one
SD in another sensitivity analysis) of the group mean
[94]. To assess the potential impact of missing SDs for
continuous outcomes, we will perform the following
sensitivity analysis.
 Where SDs are missing and it is not possible to
calculate them, we will impute SDs from trials with
similar populations and low risk of bias. If we find
no such trials, we will impute SDs from trials with a
similar population. As the final option, we will
impute SDs from all trials.
We will present results of this scenario in our review.
Other post hoc sensitivity analyses might be warranted if
unexpected clinical or statistical heterogeneity is identi-
fied during the analysis of the review results [94].
“Summary of findings” table We will create a sum-
mary of findings table using each of the prespecified out-
comes (quality of life, serious adverse events, symptom
severity, suicide and suicide attempts, self-harm, and
level of functioning) We will use the five GRADE con-
siderations (bias risk of the trials, consistency of effect,
imprecision, indirectness, and publication bias) to assess
the quality of a body of evidence as it relates to the stud-
ies which contribute data to the meta-analyses for the
prespecified outcomes [94, 105–107]. We will assess
imprecision using Trial Sequential Analysis. Otherwise,
we will use methods and recommendations described in
the Cochrane Handbook for Systematic Reviews of Inter-
ventions [83] using GRADEpro software. We will justify
all decisions to downgrade the quality of studies using
footnotes, and we will make comments to aid the
reader’s understanding of the review where necessary.
Firstly, we will present our results in the Summary of
Findings table based on the results from the trials with
low risk of bias, and secondly, we will present the results
based on all trials.
Discussion
This protocol aims at comparing the effects of short-
term psychotherapy with the effects of long-term psy-
chotherapy for common adult psychiatric disorders to
determine the best length of treatment. The outcomes
will be quality of life, serious adverse events, symptom
severity, suicide or suicide attempts, self-harm, and level
of functioning.
This protocol has a number of strengths. The predefined
methodology is based on the Cochrane Handbook for
Systematic Reviews of Interventions [83], the eight-step as-
sessment suggested by Jakobsen et al. [94], Trial Sequen-
tial Analysis [84], and GRADE assessment [105–107].
Hence, this protocol considers both risks of random errors
and risks of systematic errors. Another strength of this
protocol is that we pragmatically compare two overall
treatment strategies with each other, i.e., the results of this
review will potentially reflect the effects of the two strat-
egies in clinical everyday practice.
Our protocol also has some limitations. The primary
limitation is the potential for large heterogeneity as a result
of including all psychiatric disorders and all types of psy-
chotherapy. Therefore, we may ultimately decide that a
meta-analysis is not warranted. Further, psychotherapy al-
ways consists of multiple treatment elements and it is likely
that different interventions have different effects. Hence, if
we show a difference between the compared strategies, it
will be difficult to conclude what exactly caused the differ-
ence in effect. To minimize this limitation, a number of
subgroups are planned, but results of subgroup analyses
should always be interpreted with great caution. Another
limitation is the large number of comparisons which in-
crease the risk of type 1 error. We have adjusted our
thresholds for significance according to the number of pri-
mary outcomes, but as mentioned, we have also included
multiple subgroup analyses. This large risk of type 1 error
will be considered when interpreting the review results.
Further, we expect that no trials will have blinded treat-
ment providers and patients. Even though blinding of pa-
tients should be relatively easy, blinding of treatment
providers is theoretically possible but much more difficult
to carry out. Finally, we rely on the trialists defining their
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compared interventions as short-term and long-term (or
similar terminology). Hence, we will not include trials
comparing a short-term and a long-term version of the
same psychotherapy type, if the trialists did not explicitly
define their interventions with such terminology. Using
trialists’ definitions of short-term and long-term psycho-
therapy potentially introduces problems with heterogen-
eity. However, we believe that our choice of methodology
from a pragmatic point of view is the best solution there
is. First, trialists often report poorly and often do not
themselves use thresholds and important data might be
excluded from our review if we demand exact definitions
of lengths. Further, we do not expect to include many tri-
als in this systematic review. Hence, relying on trialists
definitions of short-term versus long-term psychotherapy
may increase the number of trials being eligible for inclu-
sion. Finally, we believe this pragmatic methodology will
lead to the inclusion of the most relevant trials.
Additional files
Additional file 1: PRISMA-P 2015 Checklist. (DOCX 30 kb)
Additional file 2: Search strategies. (DOC 46 kb)
Abbreviations
ABFT: Attachment-based family therapy; ACT: Acceptance and commitment
therapy; ADHD: Attention deficit hyperactivity disorder; CAT: Cognitive-
analytic therapy; CBT: Cognitive behavioral therapy; CENTRAL: Cochrane
Central Register of Controlled Trials; CFT: Compassion-focused therapy;
CI: Confidence interval; CPCI-S: Conference Proceedings Citation
Index—Science; CPCI-SSH: Conference Proceedings Citation Index—Social
Science & Humanities; DSM-V: Diagnostic and statistical manual of mental
disorders, 5th edition; EMA: European Medicines Agency; EMBASE: Excerpta
Medica database; GRADE: The Grading of Recommendations Assessment,
Development and Evaluation; ICD-10: International Classification of Diseases
and Related Health Problems – 10th edition; ICH-GCP: International
Conference on Harmonisation of technical requirements for registration of
pharmaceuticals for human use – Good Clinical Practice; ICTRP: International
Clinical Trials Registry Platform; MD: Mean differences; MEDLINE: Medical
Literature Analysis and Retrieval System Online; PRISMA: Preferred reporting
items for systematic review and meta-analysis; PRISMA-P: Preferred reporting
items for systematic review and meta-analysis – protocols;
PROSPERO: International Prospective Register of Systematic Reviews;
PTSD: Post-traumatic stress disorder; RR: Risk ratio; SCI-EXPANDED: Science
index citation expanded; SD: Standard deviation; SFT: Schema-Focused
Therapy; SMD: Standardized mean difference; SSCI: Social Science Citation
Index; TFP: Transference-focused psychotherapy; TRIP: Turning research into
practice; WHO: World Health Organization
Acknowledgements
The expert help from Sarah Louise Klingenberg (Information Specialist, The
Cochrane Hepato-Biliary Group, Copenhagen Trial Unit, Copenhagen,
Denmark) in making the search strategy is hugely appreciated.
Authors’ contributions
SJ wrote up the protocol with regular supervision from SP, SL, JCJ, and SS.
JCJ and SJ wrote the methods section. PS read and commented on the final
manuscript before it was submitted for publication. All authors read and
approved the final manuscript.
Funding
This study is funded by the Mental Health Services, Capital Region of
Denmark Research Fund and TrygFoundation, grant no. 123488. The funding
bodies will not be involved in design, collection, analysis, interpretation of
data, and in writing up the manuscripts.
Availability of data and materials
Data sharing is not applicable to this protocol article. We will publish all data
including code in the supplementary material of the systematic review.
Ethics approval and consent to participate
Not applicable
Consent for publication
Not applicable
Competing interests
The authors declare that they have no competing interests.
Author details
1Stolpegaard Psychotherapy Centre, Mental Health Services, Capital Region
of Denmark, Stolpegaardsvej 20, 2820 Gentofte, Denmark. 2Department of
Psychology, University of Copenhagen, Østre Farimagsgade 2A København K,
1353 Copenhagen, Denmark. 3Copenhagen Trial Unit, Tagensvej 22,
København N, 2200 Copenhagen, Denmark. 4Department of Cardiology,
Holbæk Hospital, Smedelundsgade 60, 4300 Holbæk, Denmark.
Received: 15 March 2019 Accepted: 5 July 2019
References
1. Wittchen HU, et al. The size and burden of mental disorders and other
disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;
21(9):655–79.
2. Barlow DH. The Oxford handbook of clinical psychology: updated edition.
New York: Oxford University Press; 2014.
3. American Psychiatric Association. Diagnostic and statistical manual of
mental disorders (DSM-5®). Arlington: American Psychiatric Pub; 2013.
4. Kessler RC, et al. The prevalence and correlates of adult ADHD in the United
States: results from the National Comorbidity Survey Replication. Am J
Psychiatry. 2006;163(4):716–23.
5. Fayyad J, et al. Cross-national prevalence and correlates of adult attention-
deficit hyperactivity disorder. Br J Psychiatry. 2007;190:402–9.
6. Birnbaum HG, et al. Costs of attention deficit–hyperactivity disorder (ADHD)
in the US: excess costs of persons with ADHD and their family members in
2000. Curr Med Res Opin. 2005;21(2):195–205.
7. Wittchen HU, Jacobi F. Size and burden of mental disorders in Europe-a
critical review and appraisal of 27 studies. Eur Neuropsychopharmacol. 2005;
15(4):357–76.
8. McGrath J, et al. Schizophrenia: a concise overview of incidence, prevalence,
and mortality. Epidemiol Rev. 2008;30(1):67–76.
9. Chong HY, et al. Global economic burden of schizophrenia: a systematic
review. Neuropsychiatr Dis Treat. 2016;12:357.
10. Merikangas KR, et al. Prevalence and correlates of bipolar spectrum disorder
in the world mental health survey initiative. Arch Gen Psychiatry. 2011;68(3):
241–51.
11. Dilsaver SC. An estimate of the minimum economic burden of bipolar I and
II disorders in the United States: 2009. J Affect Disord. 2011;129(1–3):79–83.
12. Compton WM, et al. Changes in the prevalence of major depression and
comorbid substance use disorders in the United States between 1991-1992
and 2001-2002. Am J Psychiatry. 2006;163(12):2141–7.
13. Greenberg PE, et al. The economic burden of adults with major
depressive disorder in the United States (2005 and 2010). J Clin
Psychiatry. 2015;76(2):155–62.
14. Kessler RC, et al. Lifetime prevalence and age-of-onset distributions of
DSM-IV disorders in the National Comorbidity Survey Replication. Arch
Gen Psychiatry. 2005;62(6):593–602.
15. DuPont RL, et al. Economic costs of anxiety disorders. Anxiety. 1996;2(4):
167–72.
16. Kessler RC, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV
disorders in the National Comorbidity Survey Replication. Arch Gen
Psychiatry. 2005;62(6):617–27.
17. Ruscio AM, et al. The epidemiology of obsessive-compulsive disorder in the
National Comorbidity Survey Replication. Mol Psychiatry. 2010;15(1):53–63.
Juul et al. Systematic Reviews           (2019) 8:169 Page 11 of 13
18. Olesen J, et al. The economic cost of brain disorders in Europe. Eur J Neurol.
2012;19(1):155–62.
19. Kessler RC, et al. Posttraumatic stress disorder in the National Comorbidity
Survey. Arch Gen Psychiatry. 1995;52(12):1048–60.
20. Goldstein RB, et al. The epidemiology of DSM-5 posttraumatic stress
disorder in the United States: results from the National Epidemiologic
Survey on Alcohol and Related Conditions-III. Soc Psychiatry Psychiatr
Epidemiol. 2016;51(8):1137–48.
21. Koenen K, et al. Posttraumatic stress disorder in the world mental health
surveys. Psychol Med. 2017;47(13):2260–74.
22. Hudson JI, et al. The prevalence and correlates of eating disorders in the
National Comorbidity Survey Replication. Biol Psychiatry. 2007;61(3):348–58.
23. Stuhldreher N, et al. Cost-of-illness studies and cost-effectiveness analyses in
eating disorders: a systematic review. Int J Eat Disord. 2012;45(4):476–91.
24. Soeteman DI, et al. The economic burden of personality disorders in mental
health care. J Clin Psychiatry. 2008;69:259–65.
25. Crits-Christoph P, Barber JP. Long-term psychotherapy. In: Snyder CR,
Ingram RE, editors. Handbook of psychological change: Psychotherapy
processes & practices for the 21st century. New York: Wiley, Inc.;
2000. p.
455–73.
26. Smit Y, et al. The effectiveness of long-term psychoanalytic psychotherapy - a
meta-analysis of randomized controlled trials. Clin Psychol Rev. 2012;32(2):81–92.
27. Leichsenring F, Rabung S. Effectiveness of long-term psychodynamic
psychotherapy: a meta-analysis. JAMA. 2008;300(13):1551–65.
28. Kernberg OF, et al. Transference focused psychotherapy: overview and
update. Int J Psychoanal. 2008;89(3):601–20.
29. Giesen-Bloo J, et al. Outpatient psychotherapy for borderline personality
disorder: randomized trial of schema-focused therapy vs transference-
focused psychotherapy. Arch Gen Psychiatry. 2006;63(6):649–58.
30. Bateman A, Fonagy P. Mentalization-based treatment for personality
disorders: a practical guide. New York: Oxford University Press; 2016.
31. Abbass AA, et al. Short-term psychodynamic psychotherapies for common
mental disorders. Cochrane Database Syst Rev. 2014;(7):CD004687.
32. Pavlov I. Conditioned reflexes: an investigation of the physiological activity
of the cerebral cortex. New York: Oxford University Press; 1927.
33. Skinner BF. Science and human behavior. New York: Macmillan; 1953.
34. Beck AT. Cognitive therapy of depression. New York: Guilford press; 1979.
35. Beck AT. Depression: clinical, experimental, and theoretical aspects.
Philadelphia: University of Pennsylvania Press; 1967.
36. Beck A, Rush A. A cognitive model of anxiety formation and anxiety
resolution. Stress Anxiety. 1975;2:69–80.
37. Salkovskis PM. Obsessional-compulsive problems: a cognitive-behavioural
analysis. Behav Res Ther. 1985;23(5):571–83.
38. Beck AT, Davis DD, Freeman A. Cognitive therapy of personality disorders.
New York: Guilford Publications; 2015.
39. Fairburn CG. Cognitive behavior therapy and eating disorders. New York:
Guilford Press; 2008.
40. Grant PM, et al. Randomized trial to evaluate the efficacy of cognitive
therapy for low-functioning patients with schizophrenia. Arch Gen
Psychiatry. 2012;69(2):121–7.
41. Sensky T, et al. A randomized controlled trial of cognitive-behavioral
therapy for persistent symptoms in schizophrenia resistant to medication.
Arch Gen Psychiatry. 2000;57(2):165–72.
42. Linehan MM, et al. Dialectical behavior therapy for high suicide risk in
individuals with borderline personality disorder: a randomized clinical trial
and component analysis. JAMA Psychiatry. 2015;72(5):475–82.
43. Farrell JM, Shaw IA, Webber MA. A schema-focused approach to group
psychotherapy for outpatients with borderline personality disorder: a
randomized controlled trial. J Behav Ther Exp Psychiatry. 2009;40(2):317–28.
44. Hayes SC. Acceptance and commitment therapy, relational frame theory,
and the third wave of behavioral and cognitive therapies. Behav Ther. 2004;
35(4):639–65.
45. Gilbert P. An introduction to compassion focused therapy in cognitive
behavior therapy. Int J Cogn Ther. 2010;3(2):97–112.
46. Ruiz FJ. A review of acceptance and commitment therapy (ACT)
empirical evidence: correlational, experimental psychopathology,
component and outcome studies. Int J Psychol Psychol Ther. 2010;10(1):
125.
47. Leaviss J, Uttley L. Psychotherapeutic benefits of compassion-focused
therapy: an early systematic review. Psychol Med. 2015;45(5):927–45.
48. Rogers CR. A theory of therapy, personality and interpersonal
relationships in the client-centred framework. In: Koch S, editor.
Psychology: a study of science. Vol III, Formulations of the person in
social context. New York: McGraw Hill; 1959. p. 184–256.
49. Perls F, Hefferline G, Goodman P. Gestalt therapy. Excitement and growth in
the human personality. New York: Julian; 1951.
50. Yalom ID. Existential psychotherapy. Vol. 1. New York: Basic Books; 1980.
51. Greenberg LS, Van Balen R. The theory of experience-centered
therapies. In: Greenberg LS, Watson JC, Lietaer G, editors. Handbook of
experiential psychotherapy. New York: Guilford Press; 1998. p. 28–57.
52. Shinohara K, et al. Behavioural therapies versus other psychological
therapies for depression. Cochrane Database Syst Rev. 2013;(10).
53. Paivio SC, Nieuwenhuis JA. Efficacy of emotion focused therapy for adult
survivors of child abuse: a preliminary study. J Trauma Stress. 2001;14(1):115–33.
54. Lock J, le Grange D. Family-based treatment of eating disorders. Int J Eat
Disord. 2005;37(S1):S64–7.
55. Diamond G, Siqueland L, Diamond GM. Attachment-based family therapy
for depressed adolescents: programmatic treatment development. Clin
Child Fam Psychol Rev. 2003;6(2):107–27.
56. Brestan EV, Eyberg SM. Effective psychosocial treatments of conduct-
disordered children and adolescents: 29 years, 82 studies, and 5,272
kids. J Clin Child Psychol. 1998;27(2):180–9.
57. Lam DH. Psychosocial family intervention in schizophrenia: a review of
empirical studies. Psychol Med. 1991;21(2):423–41.
58. Miklowitz DJ, et al. A randomized study of family-focused psychoeducation
and pharmacotherapy in the outpatient management of bipolar disorder.
Arch Gen Psychiatry. 2003;60(9):904–12.
59. O’Farrell TJ, Clements K. Review of outcome research on marital and family
therapy in treatment for alcoholism. J Marital Fam Ther. 2012;38(1):122–44.
60. Stanton MD, Shadish WR. Outcome, attrition, and family–couples treatment
for drug abuse: a meta-analysis and review of the controlled, comparative
studies. Psychol Bull. 1997;122(2):170.
61. Cuijpers P, et al. Interpersonal psychotherapy for depression: a meta-
analysis. Am J Psychiatr. 2011;168(6):581–92.
62. Ryle A, Poynton AM, Brockman BJ. Cognitive-analytic therapy: active
participation in change: A new integration in brief psychotherapy. Oxford:
Wiley; 1990.
63. Norcross JC. A primer on psychotherapy integration. In: Norcross JC,
Goldfried MR, editors. Handbook of psychotherapy integration. New York:
Basic Books; 2005. p. 3–23.
64. Critchfield KL, Benjamin LS. Principles for psychosocial treatment of
personality disorder: summary of the APA Division 12 Task Force/NASPR
review. J Clin Psychol. 2006;62(6):661–74.
65. Norcross J. Empirically supported therapy relationships. In: Norcross JC,
editor. Psychotherapy relationships that work: Therapist contributions and
responsiveness to patients. New York: Oxford University Press; 2002. p. 3–16.
66. Piper WE, et al. A comparative study of four forms of psychotherapy. J
Consult Clin Psychol. 1984;52(2):268.
67. Hoyt MF. Therapist resistances to short-term dynamic psychotherapy. J Am
Acad Psychoanal. 1985;13(1):93–112.
68. Bloom B. Planned short-term psychotherapies. In: Snyder CR, Ingram RE,
editors. Handbook of psychological change: Psychotherapy processes &
practices for the 21st century. New York: Wiley; 2000. p. 429–54.
69. Lilienfeld S. Psychological treatments that cause harm. Perspect Psychol Sci.
2007;2(1):53–70.
70. Cuijpers P, et al. How much psychotherapy is needed to treat depression? A
metaregression analysis. J Affect Disord. 2013;149(1–3):1–13.
71. Castonguay LG, et al. Practice-oriented research: approaches and applications.
Bergin Garfield’s Handb Psychother Behav Chang. 2013;6:85–133.
72. Howard KI, et al. The dose-effect relationship in psychotherapy. Am Psychol.
1986;41(2):159–64.
73. Lambert MJ, Hansen NB, Finch AE. Patient-focused research: using
patient outcome data to enhance treatment effects. J Consult Clin
Psychol. 2001;69(2):159.
74. Stulz N, et al. Dose–effect relationship in routine outpatient psychotherapy:
does treatment duration matter? J Couns Psychol. 2013;60(4):593–600.
75. Kopta SM, et al. Patterns of symptomatic recovery in psychotherapy. J
Consult Clin Psychol. 1994;62(5):1009–16.
76. Knekt P, et al. Randomized trial on the effectiveness of long-and short-term
psychodynamic psychotherapy and solution-focused therapy on psychiatric
symptoms during a 3-year follow-up. Psychol Med. 2008;38(5):689–703.
Juul et al. Systematic Reviews           (2019) 8:169 Page 12 of 13
77. Lorentzen S, et al. Comparison of short- and long-term dynamic group
psychotherapy: randomised clinical trial. Br J Psychiatry. 2013;203(3):280–7.
78. Naeem F, Farooq S, Kingdon D. Cognitive behavioural therapy (brief versus
standard duration) for schizophrenia. Cochrane Database Syst Rev. 2015;(10).
79. Moher D, et al. Preferred reporting items for systematic review and meta-
analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.
80. Shamseer L, et al. Preferred reporting items for systematic review and meta-analysis
protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;349:7647.
81. WorldHealthOrganization, International classification of diseases, 10th
revision (ICD-10). 2009.
82. International Conference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use, ICH harmonised guideline:
integrated addemdum to ICH E6(R1): guideline for good clinical practice (ICH-
GCP). 2015.
83. Higgins JP, Green S. Cochrane handbook for systematic reviews of
interventions 5.1. 0: The Cochrane Collaboration; 2011.
84. Copenhagen Trial Unit. TSA - trial sequential analysis. http://www.ctu.dk/
tsa/. [Web page]. Accessed 10 July 2019.
85. StataCorp. Stata statistical software: release 16. College Station, TX:
StataCorp LLC; 2019. http://www.stata.com
86. Moher D, et al. Preferred reporting items for systematic reviews and
meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9.
87. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis.
Stat Med. 2002;21(11):1539–58.
88. Higgins JP, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;
327(7414):557.
89. Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in
meta-analyses of controlled trials with binary endpoints. Stat Med. 2006;
25(20):3443–57.
90. Egger M, et al. Bias in meta-analysis detected by a simple, graphical test.
Bmj. 1997;315(7109):629–34.
91. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test
for publication bias. Biometrics. 1994;50:1088–101.
92. Elbourne DR, et al. Meta-analyses involving cross-over trials: methodological
issues. Int J Epidemiol. 2002;31(1):140–9.
93. Keus F, et al. Evidence at a glance: error matrix approach for overviewing
available evidence. BMC Med Res Methodol. 2010;10(1):90.
94. Jakobsen JC, et al. Thresholds for statistical and clinical significance in
systematic reviews with meta-analytic methods. BMC Med Res Methodol.
2014;14(1):120.
95. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials.
1986;7(3):177–88.
96. DeMets DL. Methods for combining randomized clinical trials: strengths and
limitations. Stat Med. 1987;6(3):341–8.
97. Wetterslev J, et al. Trial sequential analysis may establish when firm
evidence is reached in cumulative meta-analysis. J Clin Epidemiol. 2008;
61(1):64–75.
98. Brok J, et al. Trial sequential analysis reveals insufficient information size and
potentially false positive results in many meta-analyses. J Clin Epidemiol.
2008;61(8):763–9.
99. Brok J, et al. Apparently conclusive meta-analyses may be
inconclusive—trial sequential analysis adjustment of random error risk due
to repetitive testing of accumulating data in apparently conclusive neonatal
meta-analyses. Int J Epidemiol. 2008;38(1):287–98.
100. Thorlund K, et al. Can trial sequential monitoring boundaries reduce
spurious inferences from meta-analyses? Int J Epidemiol. 2008;38(1):276–86.
101. Wetterslev J, et al. Estimating required information size by quantifying
diversity in random-effects model meta-analyses. BMC Med Res Methodol.
2009;9(1):86.
102. Thorlund K, Anema A, Mills E. Interpreting meta-analysis according to the
adequacy of sample size. An example using isoniazid chemoprophylaxis for
tuberculosis in purified protein derivative negative HIV-infected individuals.
Clin Epidemiol. 2010;2:57.
103. Thorlund K, et al., User manual for trial sequential analysis (TSA). http://
www.ctu.dk/tsa/files/tsa_manual.pdf, 2011.
104. Imberger G, et al. False-positive findings in Cochrane meta-analyses with
and without application of trial sequential analysis: an empirical review. BMJ
Open. 2016;6(8):e011890.
105. Guyatt GH, et al. GRADE: an emerging consensus on rating quality of
evidence and strength of recommendations. BMJ (Clinical research ed).
2008;336(7650):924–6.
106. Schünemann HJ, et al. Letters, numbers, symbols and words: how to
communicate grades of evidence and recommendations. Can Med Assoc J.
2003;169(7):677–80.
107. Guyatt GH, et al. GRADE guidelines: a new series of articles in the Journal of
Clinical Epidemiology. J Clin Epidemiol. 2011;64(4):380–2.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Juul et al. Systematic Reviews           (2019) 8:169 Page 13 of 13
